U.S., Jan. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07326124) titled 'Stratification and Treatment in Early Psychosis Study -ASSIST' on Dec. 04, 2025.
Brief Summary: The purpose of this trial is:
* To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
* To confirm the safety of CBD in people with psychosis.
The trial is a randomised, double-blind, placebo-controlled, multi-centre, international, clinical trial. Individuals with a diagnosis of treatment resistant psychosis in their illness who have had a suboptimal or no response to clozapine treatment will be recruited. These patients ar...